Clinical Trial Update: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating pyrotinib, dalpiciclib (SHR6390), and endocrine therapy in ER+/HER2+ advanced breast cancer. Status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN